Anagenics Limited · ASX:AN1
Anagenics — Cellmid — FY2017 Earnings Presentation
29 slides from Anagenics's earnings presentation, Sep 27, 2017

Slide 1: ASX Announcement: Cellmid's FY2017 Results Presentation
ASX ANNOUNCEMENT CELLMID’S FY2017 RESULTS PRESENTATION SYDNEY: Wednesday, 27 September 2017, Cellmid Limited (ASX: CDY) is pleased to provide shareholders with the following presentation on the results of the 2017 financial year. In consumer health news, revenues for wholly owned subsidiary, Advange

Slide 2: Cellmid Limited September 2017
CELLMID LIMITED SEPTEMBER 2017 Maria Halasz CEO & Managing Director @mariahalasz

Slide 3: Important Notice
IMPORTANT NOTICE Forward looking statements This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the

Slide 4: Cellmid (CDY:ASX)
CELLMID (CDY:ASX) Fully Paid Ordinary Shares (1 September 2017) 1,068,456,303 Market Capitalisation (1 September 2017) A$ 27 million 32,500,000 Unlisted options (executive) Cash Position (30 June 2017) A$ 4 million Debt ($2 million due Feb 2019, secured against R&D Tax Credit) A$ 2.0 million

Slide 5: Corporate and Business Structure
CORPORATE AND BUSINESS STRUCTURE LYRAMID KINERA Novel FGF5 inhibitor hair Midkine antibodies for the Midkine protein for the growth products sold as treatment of fibrosis, treatment of post- OTC, non-prescription chronic kidney disease ischemic conditions natural medicines and and cancer conditions

Slide 6: Board Members
BOARD MEMBERS Dr David King | Chairman Bruce Gordon | Non-Executive Director An experienced independent chairman with expertise in Bruce is a seasoned audit partner and corporate finance high growth companies, David has a track record in specialist with over 35 years’ industry experience. Bruce buil

Slide 7: Financial Performance
FINANCIAL PERFORMANCE Financial Results 2014-2017 2014 2015 2016 2017 Total revenue and other income $ 1,898,037 $ 2,930,518 $ 4,611,108 $ 5,560,121 Consumer health revenue $ 1,150,931 $ 1,842,804 $ 2,962,306 $ 4,453,208 Midkine license revenue $ 1,009,188 $ 99,263 $ 205,390 $ 247,606 R&D tax credit

Slide 8: Consumer Health Revenue 2014 – 2017
CONSUMER HEATH REVENUE 2014 – 2017 Consumer Health Revenue Consumer health revenue up by: 286.9% from 2014 50.3% from 2016 2014 2015 2016 2017

Slide 9: Total Revenue 2014 – 2017
TOTAL REVENUE 2014 – 2017 Total Revenue Total revenue up by: 192.9% from 2014 20.6% from 2016 2014 2015 2016 2017

Slide 10: Advangen in FY2017
ADVANGEN in FY2017 • Signed distribution partnership in the US in July 2016 • Increased revenue by 50% in existing markets • Developed the global brand • Completed manufacture and launched in the US • Secured first retail partnership with Neiman Marcus • Received import permits to China

Slide 11: Lyramid Limited in FY2017
LYRAMID Limited in FY2017 • Nature publication showing that midkine has a crucial role in driving metastasis in melanoma • Pre-clinical validation programs continued in animal models of chronic kidney disease and systemic complications • Pre-clinical validation programs planned in animal models of c

Slide 12: Kinera Limited in FY2017
KINERA Limited in FY2017 • Preclinical validation of MK in chronic heart failure continued during FY2017 • GMP manufacture of MK commenced in preparation for IND-enabling studies • Preclinical studies in brain ischemia planned and partners identified

Slide 13: évolis scalp lotion products
Jo-Ju Léxilis évolis évolis SCALP LOTION SCALP LOTION PROFESSIONAL No More Bad Hair Days (advangen advanced gene science for hair “ay

Slide 14: FGF5 publications reference
*Publications on FGF5 are available via the évolis® website, www.evolisproducts.com.au/scientific-publications

Slide 15: Our Hair
d how we feel. Hair is the root of our s ea good hair day have a great day.

Slide 16: $11.6 billion 180 million
40% $11.6 billion 50% 180 million ‡ ‡ derived from US Census data 2010

Slide 17: Hair Opportunity
Hair Opportunity

Slide 18: What Makes Us Different?
WHAT MAKES US DIFFERENT ? HAIR CARE LINE CREATED BY HAIR BIOLOGISTS TO DELIVER YOUR BEST HAIR FORMULATED WITH ACOMPLETE REAL WORKING PORTFOLIO TO 100% NATURAL RESOLVE A SPECTRUM ACTIVES OF HAIR CHALLENGES évolis PROFESSIONAL REAL RESULTS BACKED BY SCIENCE

Slide 19: Hair growth cycle and FGF5
aN THE i ‘ ANAGEN : PHASE HAIR GROWTH IS) I \; \ Rui. Ba BY FGEF5 THE Ty WHAT IS FGF5: Anaturally occurring protein inthe CATAGEN $calp that controls the hairlife cycle. Stress, PHASE \ \ © genetics and environmental factors can cause an imbalance in the hair life cycle. By controlling FGFS the hair

Slide 20: Effects of FGF5 and inhibiting FGF5
NEGATIVE EFFECTS Of FGF5 WHEN YOU INHIBIT FGF5 évolis® évolis®

Slide 21: Common hair challenges and botanical actives
COMMON HAIR CHALLENGES With the botanical actives in évolis® évolis® évolis®

Slide 22: Beauty Found in Nature
Beauty Found in Nature

Slide 23: Results of Blinded Placebo Controlled Clinical Study
RESULTS OF BLINDED PLACEBO controlled Clinical STUDY 20% 44% 82% *20 faster hair growth was observed in users at 4 months. Double blinded placebo controlled study, Department of Dermatological Science, The University of Tokushima Japan (2007, Maeda et al). + The botanical actives in ‘evolis® (includ

Slide 24: Results of Consumer Usage Study
RESULTS OF CONSUMER USAGE STUDY 100% 97% 96% 87% Of users experienced Of users experienced Of users saw an Of users improved their new hair growth less hair fall improvement in hair position on the texture Norwood/Ludwig Scales 30 days 60 days 90 days 120 days Never + In a 2017 Consumer Usage Study

Slide 25: Real Users. Real Results.
CONTROL THINNING HAIR LOSS TEXTURE Day 120 Day 120

Slide 26: Big Plans for Hair
BIG PLANS FOR HAIR Looking into the future New Products to support GREAT hair

Slide 27: New products: Revive & Lift, Style & Magnify, Lash Creator, Brow Generator
Revive & Lift spray Style & Magnifycream Non-comedogenic dry shampoo, Silicone free styling cream tames effortlessly refreshes hair without hair with touchable polymers while clogging hair follicles. magnifying each strands Formulated using special micro- circumference. Hair appears boosters to inst

Slide 28: Summary
SUMMARY • Balanced portfolio of life sciences assets with strong global revenue growth from consumer health expected to continue with entering new markets • Track record of delivering sales growth year on year in the consumer health division • Major potential upside from midkine drug therapeutics (p

Slide 29: Cellmid Limited
Cellmid Limited Suite 1802, Level 18, 15 Castlereagh Street Sydney NSW 2000 AUSTRALIA T: +61 2 9221 6830 F: +61 2 9233 8975 www.cellmid.com.au www.evolisproducts.com.au www.evolisprofessional.com.au
Source: Internet Archive copy of anagenics.com
More decks from Anagenics Limited
H1 2026 Earnings Presentation12 slides · Feb 25, 2026
Shareholder Meeting (November 2025)14 slides · Nov 25, 2025
FY2025 Earnings Presentation15 slides · Aug 28, 2025
Q3 2025 Earnings Presentation15 slides · May 5, 2025
Shareholder Meeting (November 2024)12 slides · Nov 26, 2024
FY2024 Earnings Presentation14 slides · September 2024